- Home
- ABUS vs ADSE Comparison
ABUS vs ADSE Comparison
Compare ABUS & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ADSE
- Stock Information
- Founded
- ABUS 2005
- ADSE 1980
- Country
- ABUS United States
- ADSE Ireland
- Employees
- ABUS N/A
- ADSE N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ADSE Industrial Specialties
- Sector
- ABUS Health Care
- ADSE Consumer Discretionary
- Exchange
- ABUS Nasdaq
- ADSE Nasdaq
- Market Cap
- ABUS 611.0M
- ADSE 713.5M
- IPO Year
- ABUS N/A
- ADSE N/A
- Fundamental
- Price
- ABUS $3.22
- ADSE $11.61
- Analyst Decision
- ABUS Strong Buy
- ADSE
- Analyst Count
- ABUS 4
- ADSE 0
- Target Price
- ABUS $5.50
- ADSE N/A
- AVG Volume (30 Days)
- ABUS 774.3K
- ADSE 83.1K
- Earning Date
- ABUS 08-04-2025
- ADSE 09-11-2025
- Dividend Yield
- ABUS N/A
- ADSE N/A
- EPS Growth
- ABUS N/A
- ADSE N/A
- EPS
- ABUS N/A
- ADSE N/A
- Revenue
- ABUS $6,403,000.00
- ADSE $113,896,884.00
- Revenue This Year
- ABUS $3.35
- ADSE $219.58
- Revenue Next Year
- ABUS N/A
- ADSE N/A
- P/E Ratio
- ABUS N/A
- ADSE N/A
- Revenue Growth
- ABUS N/A
- ADSE 2.45
- 52 Week Low
- ABUS $2.71
- ADSE $9.00
- 52 Week High
- ABUS $4.73
- ADSE $16.35
- Technical
- Relative Strength Index (RSI)
- ABUS 48.90
- ADSE 49.80
- Support Level
- ABUS $3.08
- ADSE $10.80
- Resistance Level
- ABUS $3.30
- ADSE $11.86
- Average True Range (ATR)
- ABUS 0.10
- ADSE 0.79
- MACD
- ABUS 0.01
- ADSE 0.00
- Stochastic Oscillator
- ABUS 50.00
- ADSE 84.74
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.